NASDAQ · NTRA

Natera, Inc.

$261.99 -$2.70 (-1.02%) 1D After hours

Key Metrics

$37.91B
Market cap
P/E · TTM
$2.50B
Revenue · TTM
−$226.32M
Net income
EPS · TTM $-1.68
Dividend yield
Free cash flow $104.51M
Beta · 1Y 1.15
EBITDA · TTM −$239.09M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 17
    2 insider transaction filings hit the record.

    Form 4s are events, not verdicts — officers, directors, and 10% owners reporting their own trades. The forms post hours before the media writes them up.

    RECEIPT: SEC FORM 4 × 2, TIMESTAMPED
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 24
    The stock moved +10.7% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 24
  • May 8
    The stock moved -11.6% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 8

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$37.91B
Enterprise value
Shares outstanding143.2M
52-wk range$131.81 – $288.04
Avg volume · 20D1.3M
Net cash
Book value / share$13.17
IndustryServices-Medical Laboratories
ExchangeNASDAQ
About Natera, Inc.
IPO dateJul 2, 2015
Employees6140

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S15.16
P/FCF362.72
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating -11.4%
Net -9.0%
FCF 4.2%
ROE / ROIC -15.2% · —

Financial Health

Current ratio2.96
Quick ratio2.83
Debt / equity
Debt / EBITDA
Net cash
Working capital$1.09B

Cash Flow · TTM

Operating CF $211.02M
Capex −$106.51M
Free cash flow $104.51M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

3 / 9
Weak fundamentals · 3 of 9 signals passing

Altman Z-Score

26.6
Safe zone (> 2.99) · bankruptcy risk negligible

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings